Recovery Collaborative Group, 11,558 patient convalescent plasma late treatment RCT: no change in mortality [p=0.95] and 1% lower hospital discharge [p=0.57] https://c19p.org/recoverycp
copied to clipboard
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
, The Lancet, doi:10.1016/S0140-6736(21)00897-7 (press release 1/15/2021)
RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. NCT04381936.
|
risk of death, no change, RR 1.00, p = 0.95, treatment 1,399 of 5,795 (24.1%), control 1,408 of 5,763 (24.4%), NNT 345, day 28, primary outcome.
|
|
risk of no hospital discharge, 1.0% higher, RR 1.01, p = 0.57, treatment 1,963 of 5,795 (33.9%), control 1,941 of 5,763 (33.7%), day 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Recovery Collaborative Group et al., 1/15/2021, Randomized Controlled Trial, United Kingdom, Europe, peer-reviewed, 1 author, average treatment delay 9.0 days, trial NCT04381936.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.